Research progress of tirofiban in the treatment of mechanical thrombectomy in patients with acute ischemic stroke
10.3969/j.issn.1672-5921.2025.06.007
- VernacularTitle:替罗非班在急性缺血性卒中机械取栓治疗中的研究进展
- Author:
Yanpeng WEI
1
;
Zihao TANG
;
Jiaming XU
;
Jun SUN
Author Information
1. 325000 温州医科大学定理临床学院
- Publication Type:Journal Article
- Keywords:
Acute ischemic stroke;
Tirofiban;
Mechanical thrombectomy;
Review
- From:
Chinese Journal of Cerebrovascular Diseases
2025;22(6):424-429
- CountryChina
- Language:Chinese
-
Abstract:
Mechanical thrombectomy,which improves the successful vascular recanalization rate and neurological functional prognosis in patients with acute ischemic stroke(AIS)caused by anterior circulation large vessel occlusion,has become one of the primary therapeutic strategies.Among the pharmacologic adjuvant therapies for mechanical thrombectomy,tirofiban(a platelet glycoprotein Ⅱ b/Ⅲ a receptor antagonist)has attracted significant attention due to its antithrombotic mechanism.This article summarized the research progress of tirofiban in the mechanical thrombectomy treatment of AIS patients from the perspectives of pharmacological mechanisms,administration timing,selection of eligible populations,and dosage regimens.It also analyzed the clinical application value and existing controversies of tirofiban,aiming to provide a scientific basis for optimizing the AIS treatment system.
